Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus
Authors Evans M, Schweizer A, Foley JE
Received 5 May 2016
Accepted for publication 21 July 2016
Published 18 August 2016 Volume 2016:12 Pages 337—340
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Daniel Duprez
Marc Evans,1 Anja Schweizer,2 James E Foley3
1Diabetes Resource Centre, Llandough Hospital, Cardiff, UK; 2Medical Affairs Cardio Metabolic, Novartis Pharma AG, Basel, Switzerland; 3Medical Affairs Cardio-Metabolic, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Introduction: We have previously shown modest weight loss with vildagliptin treatment. Since body weight balance is associated with changes in blood pressure (BP) and fasting lipids, we have assessed these parameters following vildagliptin treatment.
Methods: Data were pooled from all double-blind, randomized, controlled, vildagliptin monotherapy trials on previously drug-naïve patients with type 2 diabetes mellitus who received vildagliptin 50 mg once daily (qd) or twice daily (bid; n=2,108) and wherein BP and fasting lipid data were obtained.
Results: Data from patients receiving vildagliptin 50 mg qd or bid showed reductions from baseline to week 24 in systolic BP (from 132.5±0.32 to 129.8±0.34 mmHg; P<0.0001), diastolic BP (from 81.2±0.18 to 79.6±0.19 mmHg; P<0.0001), fasting triglycerides (from 2.00±0.02 to 1.80±0.02 mmol/L; P<0.0001), very low density lipoprotein cholesterol (from 0.90±0.01 to 0.83±0.01 mmol/L; P<0.0001), and low density lipoprotein cholesterol (from 3.17±0.02 to 3.04±0.02 mmol/L; P<0.0001), whereas high density lipoprotein cholesterol increased (from 1.19±0.01 to 1.22±0.01 mmol/L; P<0.001). Weight decreased by 0.48±0.08 kg (P<0.001).
Conclusion: This large pooled analysis demonstrated that vildagliptin shows a significant reduction in BP and a favorable fasting lipid profile that are associated with modest weight loss.
Keywords: TG, HDL, LDL, body weight DPP-4 inhibitor, GLP-1
We have previously pooled data on vildagliptin monotherapy to compare body weight changes as a function of glycemic control at baseline and showed that, on an average, weight loss is observed with vildagliptin at the glycemic levels at which treatment is often initiated.1 Weight loss is associated with changes in blood pressure (BP) and fasting lipids. Data regarding BP and fasting lipids from the studies on dipeptidyl peptidase-4 (DPP-4) inhibitors are limited and may be confounded by variations among these studies in terms of the variable effects of other oral antidiabetic drugs, baseline adiposity, and insulin resistance that are also associated with changes in BP and fasting lipids.2–6
Here, we aimed to assess the impact of vildagliptin treatment on BP and fasting lipids and correlated these changes with changes in weight, body mass index (BMI), and homeostatic model assessment insulin resistance (HOMA-IR). To address these questions, we employed a large (>2,000) vildagliptin pooled monotherapy database.
Patients and study design
Data were pooled from eight, double-blind, randomized, controlled, vildagliptin monotherapy trials, including 2,108 previously drug-naïve patients with type 2 diabetes mellitus, who received vildagliptin 50 mg once daily (qd) (n=329) or twice daily (bid) (n=1,779) as a monotherapy and underwent an actual as well as a prespecified study visit, wherein weight, BP, and fasting lipids were assessed at week 24 (studies 1–3, 5, 9, and 12–14 enumerated in Table 1 from a review by Dejager et al7). The data resides in the Novartis vildagliptin database and was extracted and analyzed by Novartis database associates, as directed by the authors.
Laboratory parameters were assessed by central laboratories: Bioanalytical Research Corporation-EU (Ghent, Belgium), Diabetes Diagnostics Laboratory (Columbia, MO, USA), and Covance (Geneva, Switzerland; Singapore; or Indianapolis, IN, USA). HOMA-IR was calculated based on the following formula: HOMA-IR = (fasting insulin [uU/mL]) × (fasting glucose [mmol/L])/22.5.
A linear regression model was applied to analyze the changes in BP and fasting lipid parameters relative to body weight changes, with/without adjusting for BMI and HOMA-IR.
Ethics and good clinical practice
All study participants provided written informed consent. All protocols were approved by the independent ethics committee/institutional review board at each study site or country. All studies were conducted using Good Clinical Practice and in accordance with the Declaration of Helsinki.
This pooled analysis included 2,108 patients (54.6% male) with mean (± standard error) age 54.8±0.3 years, BMI 30.9±0.1 kg/m2, type 2 diabetes mellitus duration 2.1±0.1 years, glycated hemoglobin (HbA1c) 8.4%±0.0%, and fasting plasma glucose 9.9±0.1 mmol/L. Vildagliptin treatment (50 mg qd or bid) for 24 weeks resulted in modest but highly significant reductions in both systolic (2.70 mmHg) and diastolic (1.64 mmHg) BP. Fasting triglycerides (TG), very low density lipoprotein (VLDL) cholesterol, and low density lipoprotein (LDL) cholesterol decreased by 0.2, 0.07, and 0.13 mmol/L, respectively. Similarly, total cholesterol and non-high density lipoprotein (non-HDL) cholesterol decreased by 0.18 and 0.21 mmol/L from baseline, respectively. HDL cholesterol increased by 0.03 mmol/L and weight decreased by 0.48 kg (Table 1).
A linear regression model was used to analyze the relationship between the aforementioned BP and fasting lipid levels with weight changes, degree of adiposity as assessed by baseline BMI, and degree of insulin resistance as assessed by HOMA-IR. The changes in systolic (Figure 1A) and diastolic (Figure 1B) BP from baseline to 24 weeks relative to changes in weight showed positive slopes of 0.71 (r2=0.04; P<0.001) and 0.40 (r2=0.03; P<0.001), respectively. These values did not improve by adjusting for BMI and HOMA-IR. Positive slopes of 0.023 (r2=0.01; P<0.0001) and 0.010 (r2=0.01; P<0.0001) were observed for changes in TG (Figure 1C) and VLDL cholesterol (Figure 1D) levels from baseline to 24 weeks relative to changes in weight. These values improved to 0.028 (r2=0.03; P<0.0001) and 0.013 (r2=0.04; P<0.0001), respectively, by adjusting for BMI and HOMA-IR. Total cholesterol, LDL, and non-HDL cholesterol did not correlate with weight change, with or without adjusting for BMI or HOMA-IR. Changes in HDL cholesterol (Figure 1E) at 24 weeks relative to changes in weight showed a negative slope of 0.005 (r2=0.009; P<0.0001), and this value did not improve by adjusting for BMI and HOMA-IR.
We have previously shown that, on an average, weight neutrality is essentially observed at higher baselines with vildagliptin, while a weight loss of ~1 kg was observed in patients with baseline HbA1c <8% (64 mmol/mol).1 The current analysis also demonstrated significant reductions in BP with a favorable fasting lipid profile. The slopes of these parameters versus weight change suggest that these changes are at least partially explained by weight reduction. Because weight reduction is greatest at glycemic levels where patients are most often treated,1 BP and fasting lipid benefits may actually be therapeutically greater than those indicated by the averages in this pooled analysis. There is no mechanistic basis for predicting that similar results would not be seen with other DPP-4 inhibitors.
Both vildagliptin 50 mg qd or bid are indicated as monotherapy in many countries and clinical trials were carried out with both dosing frequencies. We have previously shown that when baseline HbA1c levels were below 8% there was no additional HbA1c reduction benefit to the twice daily dosing frequency with monotherapy.7 Sixteen percent of the patients in the current analysis were on the 50 mg qd dose; notably the 50 mg qd group was 4 years older and had baseline HbA1c levels 1.2% lower than the 50 mg bid group. Weight loss was greater in the 50 mg qd group (−1.2 kg in the 50 mg qd group versus −0.4 kg in the 50 mg bid group) as predicted previously by the lower baseline HbA1c and presumably lower degree of glycosuria1 in the 50 mg qd group; the reduction in diastolic BP was ~50% greater and the TG reduction was ~50% lower (from a lower TG baseline of 1.8 versus 2.0 mmol/L) in the 50 mg qd group versus the 50 mg bid group; the correlations were not driven by inclusion of the 50 mg qd dose (data not shown). None of the differences were considered notable enough to justify reporting the data in independent pools and thus we have chosen to report the BP and fasting lipids results in a single pool as we did previously with the weight.1
The BP and fasting lipids results are associated with some caveats. The average weight change is small (approximately −0.5 kg), and the measurements of BP and weight in the large clinical trials utilized for the current pool are expected to be associated with a high degree of variability, which presumably explains the reason for low correlation coefficient (r2). In contrast, the n value is very high, hence yielding significant slopes. Partial correlation analysis suggests that the changes in TG and VLDL cholesterol are also partially explained by the degree of adiposity and insulin resistance. These effects of adiposity and insulin resistance or the lack thereof must be interpreted with some caution due to the limitations of the BMI and HOMA-IR surrogates of adiposity and insulin resistance measured in these clinical trials. Furthermore, the studies pooled for this analysis were designed to assess BP and fasting lipids as secondary endpoints, and no data on confounding BP and lipid medications were collected.
Thus, therapeutically, DPP-4 inhibitors yield modest benefits of unknown clinical importance on BP and fasting lipids. Although these BP and fasting lipid benefits of DPP-4 inhibitors have not translated into cardiovascular risk reduction over 3 years,8 it is possible that a primary prevention trial of longer duration might contribute to a cardiovascular benefit after a longer follow-up. Notably, hypotension has not been identified as a side effect with vildagliptin.9
This study was funded by Novartis Pharma AG. The authors thank Nihal Maremanda, Novartis Healthcare Pvt. Ltd., Hyderabad, India, for the editorial support.
ME has received honoraria as an advisory panel member and is a speaker for Novo Nordisk, Sanofi Aventis, Novartis, and MSD. JEF and AS are employed by and own shares in Novartis.
Blüher M, Schweizer A, Bader G, Foley JE. Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. Vasc Health Risk Manag. 2014;10:661–664.
Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord. 2002;26(1):48–57.
Flock MR, Green MH, Kris-Etherton PM. Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol. Adv Nutr. 2011;2(3):261–274.
Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56(2):320–328.
Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26(2):19–39.
Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878–884.
Dejager S, Schweizer A, Foley JE. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vasc Health Risk Manag. 2012;8:339–348.
Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
Galvus® Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf. Accessed July 13, 2016.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]